SEONGNAM, South Korea, April 6, 2025 /PRNewswire/ -- ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative ...
Morning Overview on MSN
New bio-implant could finally repair broken spinal cords
A series of converging advances in bio-implant technology, from brain-spine interfaces to lab-grown spinal tissue, is ...
SANTA FE, N.M., Oct. 1, 2025 /PRNewswire/ -- Mercury Bio (www.mercurybio.com), a drug delivery company leveraging its novel and proprietary extracellular vesicle (EV) drug encapsulation platform (yEV™ ...
SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous system (CNS), today ...
Highlight brain imaging analysis solutions, including 'Neurophet AQUA AD', which monitors side effects from Alzheimer's disease treatments To accelerate partnering efforts with global pharmaceutical ...
JuneBrain Inc., a Baltimore-based neurotech startup, took first place at the 2025 BioChallenge Pitch Competition, held October 30 at the New Orleans BioInnovation Center (NOBIC). The annual contest ...
BrainChild Bio advancing BCB-276 towards BLA submission with a single pivotal Phase 2 trial planned to commence in Q4 2025 SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BrainChild Bio, Inc., a clinical ...
Shanghai-based D3 Bio (Wuxi) Co. Ltd. showed positive results for its lead candidate, next-generation KRAS G12C inhibitor, D3S-001, also known as elisrasib, in patients with KRAS G12C mutation cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results